Y., W., N., S., S., T., J., Y., B., H., B., M., . . . M., F. (2017). Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Chicago Style CitationY., Wu, et al. Efficacy According to Blind Independent Central Review: Post-hoc Analyses From the Phase III, Randomized, Multicenter, IPASS Study of First-line Gefitinib Versus Carboplatin/paclitaxel in Asian Patients With EGFR Mutation-positive Advanced NSCLC. 2017.
MLA引文Y., Wu, et al. Efficacy According to Blind Independent Central Review: Post-hoc Analyses From the Phase III, Randomized, Multicenter, IPASS Study of First-line Gefitinib Versus Carboplatin/paclitaxel in Asian Patients With EGFR Mutation-positive Advanced NSCLC. 2017.